We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 06, 2020

Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
J. Clin. Oncol 2019 Dec 27;[EPub Ahead of Print], AA Tarhini, SJ Lee, FS Hodi, UNM Rao, GI Cohen, O Hamid, LF Hutchins, JA Sosman, HM Kluger, Z Eroglu, HB Koon, DP Lawrence, KL Kendra, DR Minor, CB Lee, MR Albertini, LE Flaherty, TM Petrella, H Streicher, VK Sondak, JM Kirkwood

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading